Condition

Castration-resistant Prostate Cancer clinical trials and research

• 15Clinical trials
• 76NIH research projects
• 8Countries

Newest Castration-resistant Prostate Cancer clinical trials

All recruiting trials (15)

• MRT-2359 plus apalutamide in advanced prostate cancer

  This Phase 2 trial tests whether taking MRT-2359 with apalutamide can lower PSA in men with castration-resistant prostate cancer.

  Recruiting at 7 sites Phase 2 Monte Rosa Therapeutics, Inc · Los Angeles, California and 13 other locations · NCT07745361

• JANX014 for metastatic castration-resistant prostate cancer

  This trial will test whether JANX014 is safe, how your body handles it, and whether it shows signs of benefit in adults with metastatic castration-resistant prostate cancer who have already had anti-androgen therapy and typically a taxane.

  Recruiting at 6 sites Phase 1 Janux Therapeutics · La Jolla, California and 5 other locations · NCT07545811

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• Terbium‑161 RAD402 treatment for castration‑resistant prostate cancer

  This will test a radioactive antibody called 161Tb‑RAD402 to see if it is safe and can help men with castration‑resistant prostate cancer whose disease has progressed after prior treatments.

  Recruiting at 2 sites Phase 1/2 Radiopharm Theranostics, Ltd · Wollongong, New South Wales and 1 other locations · NCT07259213

• DCC-2812 in advanced kidney, bladder, and castration-resistant prostate cancers

  This trial will test whether the oral drug DCC-2812 is safe and shows early signs of benefit for people with advanced kidney (renal cell), bladder (urothelial), or castration-resistant prostate cancer.

  Recruiting at 8 sites Phase 1 Deciphera Pharmaceuticals, LLC · Boston, Massachusetts and 7 other locations · NCT06966024

• GZ17-6.02 treatment for advanced prostate cancer after hormone therapy

  This study is testing a new treatment called GZ17-6.02 to see if it can help men with advanced prostate cancer that hasn't responded to hormone therapy.

  Recruiting Phase 1 Virginia Commonwealth University · Richmond, Virginia · NCT06636123

• Treatment for prostate cancer with limited metastasis

  This study is testing whether a new treatment for prostate cancer with a few spreading spots can help patients live longer by comparing radiotherapy to surgery.

  Recruiting Phase 3 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT06585007

• Combining radiation therapy with hormone treatments for advanced prostate cancer

  This study is testing if combining a specific type of radiation therapy with hormone treatments can help men with advanced prostate cancer live longer and feel better compared to just using radiation alone.

  Recruiting at 3 sites Phase 2 Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT06378866

• New targeted treatment for advanced prostate cancer using a radioactive compound

  This study is testing a new radioactive treatment for advanced prostate cancer to see if it works better than current options and to find the best dose that helps patients with fewer side effects.

  Recruiting Phase 1 University Hospital, Basel, Switzerland · Basel · NCT06343038

• Comparing imaging methods for prostate cancer treatment evaluation

  This study is testing whether whole body MRI is better than bone scans and CT scans for checking how well treatments are working in men with advanced prostate cancer.

  Recruiting European Institute of Oncology · Milan · NCT06321679

• Using blood tests to predict treatment response in advanced prostate cancer

  This study is testing if blood tests can help predict how well men with advanced prostate cancer will respond to their treatment.

  Recruiting at 3 sites Duke University · New York, New York and 2 other locations · NCT06141993

• Evaluating PSMA Changes in Prostate Cancer After Hormonal Therapy

  This study is testing how hormonal therapy changes a specific protein in men with prostate cancer to see if those changes can help doctors understand the cancer better.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT05919329

• Combining apalutamide and carotuximab for advanced prostate cancer

  This study is testing if combining two drugs, apalutamide and carotuximab, can help men with advanced prostate cancer who haven't responded to other treatments feel better and live longer.

  Recruiting at 3 sites Phase 2 Cedars-Sinai Medical Center · Duarte, California and 2 other locations · NCT05534646

• Using targeted radiation therapy for prostate cancer that resists standard treatment

  This study is testing a new type of targeted radiation therapy for men with prostate cancer that isn't responding to standard treatment, to see if it can help control their cancer while they continue their current medication.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT04838899

• Combining Bipolar Androgen Therapy with Carboplatin for Advanced Prostate Cancer

  This study is testing if combining a new hormone treatment with a chemotherapy drug can help men with advanced prostate cancer that hasn't responded to other treatments.

  Recruiting Phase 2 St Vincent's Hospital, Sydney · Sydney, New South Wales · NCT03522064

NIH-funded research (newest 40 of 76)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding how aggressive cell states emerge in castration-resistant prostate cancer

  A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.

  NIH research State University New York Stony Brook · Stony Brook, United States · NIH-11463275

• Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer

  Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.

  NIH research University of Maryland Baltimore · Baltimore, United States · NIH-11452128

• Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer

  Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11427360

• Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy

  This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.

  NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11419184

• Hyperactive methylation in a hard-to-treat prostate cancer subtype

  Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11415138

• Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer

  A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11411377

• Stopping therapy-resistant prostate cancer by blocking FOXA2 and AP-1

  This research looks at whether blocking a protein switch called FOXA2 and its partner AP‑1 can stop or reverse prostate cancers that no longer respond to hormone therapy.

  NIH research University of Massachusetts Boston · Boston, United States · NIH-11404787

• New approach to treating castration-resistant prostate cancer

  A researcher is exploring a new mechanism that could be targeted to treat castration-resistant prostate cancer (CRPC), especially in veterans, by understanding how certain signaling pathways drive resistance to current therapies.

  NIH research Veterans Health Administration · Long Beach, United States · NIH-11402383

• Ceramide-based therapy targeting SMS1 to treat advanced prostate cancer

  A new approach aims to slow or stop castration-resistant prostate cancer in men 65 and older by using molecules that mimic ceramide to block a key enzyme, potentially helping those whose cancer no longer responds to standard treatments.

  NIH research Idaho State University · Pocatello, United States · NIH-11401194

• Targeting immune-suppressing macrophages to help African American men with advanced prostate cancer

  Aims to improve treatment for metastatic castration-resistant prostate cancer by changing the behavior of immune cells in tumors to help the body fight the cancer, with a focus on African American patients who are at higher risk.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11390865

• Targeting STING Pathways in SPOP-Mutant Prostate Cancer

  A precision cancer study explores how STING signaling changes in a specific form of prostate cancer to find new treatment approaches.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11384741

• Targeting CD206+ macrophages to boost immune attack against metastatic prostate cancer

  A Johns Hopkins team is testing a new approach to help the body's own immune system fight metastatic castration-resistant prostate cancer by switching tumor-associated macrophages from immune-suppressing to anti-tumor supporters.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11377596

• Biomarker to tailor hormone therapy for prostate cancer

  A doctor-and-patient friendly look at a study that tests whether a specific genetic variant can guide when to use intensified hormone therapy for advanced prostate cancer.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11377377

• CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer

  A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-11370143

• Prostate cancer: a new combination approach using ARSI therapy with CD105 blocker to overcome resistance

  A new treatment concept aims to help men with advanced prostate cancer that stops responding to standard ARSI therapy by pairing ARSI treatment with a CD105 blocker to tackle resistance.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11360657

• Targeting metabolic weaknesses in castration-resistant prostate cancer with high-dose androgen combinations

  This grant supports a doctor-researcher in a five-year program to uncover metabolic vulnerabilities in advanced prostate cancer and develop new combination therapies using high-dose androgens.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11358369

• Overcoming drug resistance in advanced prostate cancer

  This NIH grant aims to find new ways to treat castration-resistant prostate cancer by targeting how EZH2 works and how Plk1 may influence it.

  NIH research University of Kentucky · Lexington, United States · NIH-11352531

• Targeted drugs that hit the androgen receptor and epigenetic switches in castration-resistant prostate cancer

  A new small molecule treatment aims to block the androgen receptor and disrupt epigenetic regulation to slow or stop progression of castration-resistant prostate cancer in men.

  NIH research Georgia Institute of Technology · Atlanta, United States · NIH-11337536

• Targeting B7-H3 with TriKEs to treat metastatic prostate cancer

  A Mayo Clinic team is testing a TriKE therapy that directs natural killer cells to attack metastatic prostate cancer in men.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11334072

• Targeting DNA replication stress in SPOP-mutant prostate cancer

  A Mayo Clinic-led study aims to find a new way to treat prostate cancer that has become resistant to standard therapy, by exploiting a specific genetic alteration (SPOP mutations).

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11334071

• BAT with carboplatin for TP53-altered prostate cancer

  This project tests a combination treatment using high-dose testosterone swings plus carboplatin for men whose prostate cancer has changed TP53 status and progressed after standard therapies.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11334070

• Targeting Plk1, Pdcd4, and mTORC2 to Treat Castration-Resistant Prostate Cancer

  A study from the University of Kentucky aims to find new ways to treat castration-resistant prostate cancer by focusing on how certain cell signals interact, with the potential to help men whose cancer no longer responds to current hormone therapies.

  NIH research University of Kentucky · Lexington, United States · NIH-11332921

• A new targeted treatment for advanced prostate cancer that no longer responds to hormones

  This project aims to create a PSMA-targeted therapy that delivers a microtubule‑blocking drug to tumors in people with metastatic castration‑resistant prostate cancer (mCRPC).

  NIH research University of Texas Hlth Sci Ctr Houston · Houston, United States · NIH-11321671

• Optimizing gamma/delta CAR-T therapy for bone-ed metastatic prostate cancer

  A patient-focused overview: this grant aims to improve a patient’s own CAR-T cell therapy for bone-dominant, advanced prostate cancer to make it more effective and safer.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11319233

• Using an oral LSD1 blocker to target aggressive castration-resistant prostate cancer

  Seeing if an oral drug that blocks the LSD1 enzyme can kill or slow aggressive neuroendocrine and castration-resistant prostate cancers.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11301841

• How a protein complex helps genetic messages leave cells in advanced prostate cancer

  This project looks at whether blocking a protein complex that helps send genetic messages (mRNA) out of the cell nucleus can slow the growth and spread of castration‑resistant prostate cancer.

  NIH research University of Virginia · Charlottesville, United States · NIH-11285441

• Investigating how a protein complex affects the movement of RNA in advanced prostate cancer.

  This study is looking at how a specific protein complex helps move important messages in cells related to castration-resistant prostate cancer, with the hope of finding new ways to improve treatment for patients dealing with this tough form of cancer.

  NIH research University of Virginia · Charlottesville, United States · NIH-11251381

• Blood test to track treatment resistance in advanced prostate cancer

  This project uses a blood-based DNA fragment test plus AI to spot molecular changes that signal treatment resistance in men with metastatic castration-resistant prostate cancer.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11249567

• New treatments targeting B7-H3 for advanced prostate cancer

  Testing whether therapies that target the B7-H3 protein can help men with castration-resistant prostate cancer, especially tumors with PTEN and TP53 changes.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11245738

• Blocking PTPN1 to fight hormone‑resistant prostate cancer

  This project looks for ways to block a protein called PTPN1 that helps some prostate cancers stop responding to hormone treatments, with the goal of finding new treatment or detection options.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11238970

• Androgen receptor changes in castration-resistant prostate cancer

  Looks at whether changes in the androgen receptor let prostate cancer survive hormone therapy and whether those weaknesses can be targeted to help men with castration-resistant prostate cancer.

  NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11198064

• How the protein YY1 helps advanced, treatment-resistant prostate cancer grow

  This research explores if targeting the protein YY1 can slow or stop growth of castration-resistant prostate cancer that no longer responds to hormone therapy.

  NIH research Duke University · Durham, United States · NIH-11190789

• A newly discovered heavily methylated form of advanced prostate cancer

  Researchers are looking at a newly found heavily methylated type of advanced prostate cancer to find markers and possible weak points for treatment in men with metastatic castration‑resistant prostate cancer.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11181255

• Helping immunotherapy work for metastatic prostate cancer

  A new antibody aims to help men with metastatic castration-resistant prostate cancer respond to immunotherapy by blocking an immune-suppressing molecule released by tumors.

  NIH research Northwestern University · Chicago, United States · NIH-11181018

• Stopping treatment-resistant cell changes in advanced prostate cancer

  This effort tries to stop advanced prostate cancer in men from changing into more aggressive, treatment-resistant forms.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11173732

• Blocking lipid signaling to treat advanced, hormone‑resistant prostate cancer

  This project aims to block lipid signaling with potent inhibitors to help men whose prostate cancer no longer responds to hormone therapy.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11170557

• Targeting STING signaling in SPOP‑mutant castration‑resistant prostate cancer

  This project tests whether blocking a specific STING immune pathway can help men with castration‑resistant prostate cancer that carry SPOP mutations.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11168771

• Targeting microtubule dynamics to treat advanced prostate cancer

  This study is testing a new treatment for men with advanced prostate cancer that doesn't respond to hormone therapy, using special molecules that target cancer cells to help improve the effectiveness of the therapy while protecting healthy tissue, and you might have a chance to join the trials to see how well it works.

  NIH research University of Texas Hlth Sci Ctr Houston · Houston, United States · NIH-11167485

• Understanding a genetic marker for prostate cancer that resists treatment

  This work aims to find a genetic clue that helps doctors choose the best treatment for men with prostate cancer that has become resistant to standard hormone therapy.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11143262

• New Treatment Approaches for Castration-Resistant Prostate Cancer

  This research looks for new ways to treat prostate cancer that has become resistant to standard hormone therapies.

  NIH research University of Kentucky · Lexington, United States · NIH-11131062

Related topics

Quick answers

How many Castration-resistant Prostate Cancer clinical trials are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 8 countries. The most sites are in United States (9 trials), Australia (2 trials), Belgium (1 trial), Georgia (1 trial), Spain (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 5, Phase 2: 4, Phase 3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →